ABSTRACT Introduction: Pelvic fracture urethral injuries (PFUI) often lead to erectile dysfunction (ED) and recurrent urethral strictures due to fibrosis post-urethroplasty. Tadalafil, commonly used for treating ED, has demonstrated antifibrotic properties in animal studies. This study evaluates the efficacy of tadalafil in improving surgical outcomes in PFUI urethroplasty in humans. Materials and Methods: A prospective study was conducted on 40 male patients undergoing urethroplasty for PFUI from January 2023 to January 2024. Patients were divided into two groups: Group 1 ( n = 20) received 5 mg tadalafil daily postoperatively for 3 months, while Group 2 ( n = 20) did not receive tadalafil. Outcomes were assessed based on the success rate (symptom resolution and no need for further intervention) and complication rates. Results: The tadalafil group had a higher success rate (80%) compared to the non-tadalafil group (60%), with fewer complications (20% vs. 40%, P < 0.05). Redo urethroplasty and dilatation rates were also lower in the tadalafil group. Conclusion: Postoperative use of tadalafil significantly improved surgical outcomes in PFUI urethroplasty by reducing fibrosis and complications. Tadalafil may serve as a promising adjunct in urethral reconstruction, though larger studies are recommended to confirm these findings.
Garg et al. (Thu,) studied this question.